The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

Summary

MICS CABG (Minimally invasive coronary surgery), where coronary artery bypass grafting (CABG) is completed through a small incision over the left chest, has evolved to become a safe and less invasive alternative to conventional sternotomy CABG. Several observational studies have suggested significantly shorter time to return to physical activity for MICS CABG patients compared to sternotomy CABG patients. A randomized study is warranted to validate these findings, provide higher level of evidence, and potentially lead to changes in practice. The MIST Trial is a multi-centre, prospective, open label, randomized control trial comparing quality of life and recovery in the early post-operative period, between patients undergoing MICS CABG versus patients undergoing sternotomy CABG. Patients referred for isolated CABG for multi-vessel coronary artery disease and deemed technically suitable for sternotomy CABG as well as for MICS CABG are considered for enrollment into the trial. Quality of life questionnaires (The SF-36, Seattle Angina Questionnaire and EQ-5D-5L) will be used to assess the quality of life and recovery in patients undergoing sternotomy CABG or MICS CABG at 1 month, 3 months, 6 months and 12 months follow up.

Conditions

• Coronary Artery Disease

Interventions

PROCEDURE

MICS CABG

Coronary artery bypass grafting performed through small incisions between the ribs.

PROCEDURE

Conventional CABG

Coronary artery bypass grafting performed through an incision through the sternum or breastbone.

Sponsors & Collaborators

• London Health Sciences Centre

  collaborator OTHER

• Heart Center Leipzig - University Hospital

  collaborator OTHER

• Fortis Escorts Heart Institute

  collaborator OTHER

• The Methodist Hospital Research Institute

  collaborator OTHER

• Carolinas Medical Center

  collaborator OTHER

• Gundersen Lutheran Health System

  collaborator OTHER

• Jilin Heart Hospital

  collaborator OTHER

• Far Eastern Memorial Hospital

  collaborator OTHER

• Medtronic

  collaborator INDUSTRY

• Apollo Hospitals Enterprise Limited

  collaborator OTHER

• Fresno Heart and Surgical Hospital

  collaborator UNKNOWN

• Ichinomiya-Nishi Hospital

  collaborator UNKNOWN

• Ottawa Heart Institute Research Corporation

  lead OTHER

Principal Investigators

• Marc Ruel, MD · Ottawa Heart Institute Research Corporation

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-09-01

Primary Completion

2025-01-31

Completion

2028-03-01

Countries

• United States
• Belgium
• Canada
• China
• Germany
• India
• Japan
• Singapore
• Taiwan

Study Locations